Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI develops real-time optical coherence tomography imaging systems and artificial-intelligence tools for cancer surgery. The company’s Claire OCT+AI device has FDA premarket approval for intraoperative breast cancer margin assessment, while its S-Series OCT platform provides ultra-high-resolution cross-sectional visualization of excised tissue.
Company news commonly covers FDA regulatory milestones, product demonstrations, commercialization activity, clinical and technology updates, operating and financial results, investor conference presentations, and capital-structure actions such as private placements, warrants, and stock-option matters.
Summary not available.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) announced its participation at the 24th Annual Meeting of the American Society of Breast Surgeons (ASBrS) from April 26-30, 2023, in Boston, MA. The company will host an educational symposium titled "ACT IN THE MOMENT: OCT adds real-time clarity on margin status," featuring prominent breast surgeons who will share their experiences utilizing the Perimeter S-Series Optical Coherence Tomography (OCT) technology. This device provides real-time imaging to assist surgeons during procedures. Perimeter will also offer live demonstrations at Booth #923, showcasing the OCT system's capabilities in visualizing tissue margins at a cellular level. The event underscores Perimeter's commitment to advancing breast cancer surgery technology.
Perimeter Medical Imaging AI, Inc. (OTC: PYNKF) announced the first commercial placement of its Perimeter S-Series OCT system in Utah on April 25, 2023. This FDA-cleared imaging tool, launched in 2021, enhances cancer surgery with real-time, cross-sectional visualization of excised tissues. Dr. Jennifer J. Tittensor, a breast surgeon, will utilize the system to improve margin assessments during surgeries. Perimeter's CEO, Jeremy Sobotta, noted growing interest from surgeons, indicating a positive sales momentum. The company is also advancing its next-generation Perimeter B-Series OCT with ImgAssist AI, supported by a grant of up to $7.4 million from the Cancer Prevention and Research Institute of Texas, highlighting its commitment to innovation in oncological surgery.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25-26, 2023, in Toronto. The company, focused on revolutionizing cancer surgery through advanced imaging technologies, aims to address significant unmet medical needs.
Key details include:
- Company Presentation: April 26, 2023, from 11:00-11:30 AM ET.
- Webcast Link: Register here.
- Presenter: Jeremy Sobotta, CEO.
Perimeter aims to enhance surgical outcomes with its Perimeter S-Series OCT system and investigates the Perimeter B-Series OCT with cutting-edge AI technology, supported by a US$7.4 million grant for clinical trials.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) reported its financial results for the year ended December 31, 2022, revealing a net loss of $9.9 million, down from $13.3 million in 2021. Operating expenses rose to $16.6 million from $12.9 million, with cash used in operations at $11.9 million. The company successfully completed a private placement generating C$48.7 million and doubled its commercial installed base of the Perimeter S-Series OCT in Q4 2022. All eight clinical trial sites for the B-Series OCT system were activated, with expansion authorized. The company anticipates completion of patient enrollment in its trial by the end of 2023.
Additionally, the company aims to enhance the surgical outcomes during breast conservation surgery through its innovative imaging technology.
Perimeter Medical Imaging AI, Inc. (PYNKF) will announce its financial and operational results for the year ending December 31, 2022, on April 11, 2023, after U.S. market close. The company aims to transform cancer surgery through advanced imaging technology. The conference call is scheduled for the same day at 5 PM ET, featuring CEO Jeremy Sobotta. Investors can join via a dial-in number or a webcast. The Perimeter S-Series OCT system is FDA-cleared for real-time visualization of excised tissues, while the B-Series OCT is undergoing pivotal trials with funding support of up to $7.4 million from the Cancer Prevention and Research Institute of Texas.
Perimeter Medical Imaging AI has published a new white paper on the efficacy of its Perimeter S-Series OCT technology in breast conserving surgeries for ductal carcinoma in situ. The paper, authored by Dr. Amelia Tower, outlines three case studies where the technology enabled real-time margin visualization, allowing for intraoperative decisions that eliminated the need for additional surgeries. CEO Jeremy Sobotta highlighted the technology's potential to improve patient outcomes and reduce healthcare costs. The white paper was also presented at the SSO 2023 International Conference, showcasing Perimeter's commitment to advancing cancer surgery through innovative imaging tools.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) announced its participation in the Society of Surgical Oncology's International Conference on Surgical Cancer Care (SSO 2023) from March 22-25, 2023, in Boston, MA. The company will feature its S-Series OCT device during a spotlight presentation and demonstrations. This advanced imaging technology enhances margin assessment in real-time during surgeries, aiming to improve patient outcomes by reducing the need for repeat surgeries. Additionally, Perimeter engaged Red Cloud Securities for liquidity services to boost market stability and share liquidity, commencing March 15, 2023.
Perimeter Medical Imaging AI, a commercial-stage medical technology company, announced its AI technology is featured in the "Artificial Intelligence: Your Mind & The Machine" exhibit at the Museum of Science & History (MoSH) in Memphis, TN, running until May 6, 2023. The company’s CEO, Jeremy Sobotta, emphasized the significance of their next-gen ultra-high resolution optical imaging technology being evaluated in clinical trials at the West Cancer Center. Supported by AI industry leaders, Perimeter aims to enhance surgical decision-making for cancer patients. The company’s innovative imaging systems are FDA-cleared and are backed by a grant of up to $7.4 million from the Cancer Prevention and Research Institute of Texas.
Perimeter Medical Imaging AI (PYNKF) announced significant leadership changes, appointing Suzanne Foster as the new Chair of the Board of Directors. Effective immediately, her extensive background in healthcare will enhance the company's mission in cancer surgery technology. CEO Jeremy Sobotta expressed confidence in Foster's leadership, praising her experience within the organization. Former Chair Dr. Anthony Holler remains as a director. Additionally, Chris Scott resigned as CFO, with Russell Wagner stepping in as Interim CFO while a search for Scott’s replacement begins. Perimeter aims to leverage its advanced imaging technology to improve patient outcomes.